Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07817251 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema

Name: Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema — clinical trial record (NCT07817251)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorNovo Nordisk A/S

Started2026-09-16

View on ClinicalTrials.gov ↗

The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in this clinical study for about 6 months.

Trial Details

NCT Number	NCT07817251
Lead Sponsor	Novo Nordisk A/S
Conditions	Diabetes Mellitus, Type 2
Enrollment	210 participants
Start Date	2026-09-16
Primary Completion	2027-06-09 (estimated)
Study Completion	2027-07-21 (estimated)
Updated on ClinicalTrials.gov	2026-09-14